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Summary
Crystal structures of H. marismortui large ribosomal
subunits containing the mutation G2099A (A2058 in
E. coli ) with erythromycin, azithromycin, clindamycin,
virginiamycin S, and telithromycin bound explain why
eubacterial ribosomes containing the mutation A2058G
are resistant to them. Azithromycin binds almost
identically to both G2099A and wild-type subunits,
but the erythromycin affinity increases by more than
104-fold, implying that desolvation of the N2 of G2099
accounts for the low wild-type affinity for macrolides.
All macrolides bind similarly to the H. marismortui
subunit, but their binding differs significantly from
what has been reported in the D. radioidurans sub-
unit. The synergy in the binding of streptogramins A
and B appears to result from a reorientation of the
base of A2103 (A2062, E. coli ) that stacks between
them. The structure of large subunit containing a
three residue deletion mutant of L22 shows a change
in the L22 structure and exit tunnel shape that illumi-
nates its macrolide resistance phenotype.
Introduction
Many clinically important antibiotics specifically inhibit
the activity of eubacterial ribosomes, and prominent
among them are the macrolide, lincosamide, strepto-
gramin B, and ketolide antibiotics, which are often called
the MLSBK antibiotics. All members of this chemically
heterogeneous group bind to the peptidyl transferase
center of the large ribosomal subunit at sites that are
close to each other or overlapping (Spahn and Pres-
cott, 1996), and bacterial strains resistant to any one of
them tend to be resistant to all.
Bacterial strains resistant to MLSBK antibiotics com-
monly contain either an N-methyl transferase that
methylates the exocyclic N6 amine of A2058 (E. coli
numbering) in 23S rRNA or a mutated 23S rRNA, often
A2058G (Weisblum, 1995). Resistance mutations also
occur in the loops of ribosomal proteins L4 and L22,
which come close together in the wall of the peptide
exit tunnel, not far from where MLS K antibiotics bindB*Correspondence: eatherton@csb.yale.edu
4 These authors contributed equally to this work.
5 Present address: Department of Molecular and Cellular Physiol-
ogy, Stanford University, Stanford, California 94305.(Chittum and Champney, 1994; Malbruny et al., 2002;
Wittmann et al., 1973).
In the last two years, crystal structures have been
published for several MLSBK antibiotics bound to the
large ribosomal subunits. Yonath and coworkers have
obtained structures of Deinococcus radiodurans (Dra)
large ribosomal subunit complexed with erythromycin
and telithromycin, which are 14-membered macrolides,
a lincosamide, clindamycin, and dalfopristin and quinu-
pristin, which are streptogramins of the A and B types,
respectively (Berisio et al., 2003; Harms et al., 2004;
Schlu¨nzen et al., 2001). The structures of the 15-mem-
bered macrolide, azithromycin, the 16-membered mac-
rolides, carbomycin A, spiramycin, and tylosin, and
finally virginiamycin M, which is an A-type strepto-
gramin, bound to the large ribosomal subunit from Ha-
loarcula marismortui (Hma) have also been determined
(Hansen et al., 2002a; Hansen et al., 2003). While the
locations of the MLSBK antibiotic binding sites on the
ribosomes from both species are grossly similar, there
are surprising differences in detail. The conformations
of many of these antibiotics as well as their interactions
with the surrounding ribosomal structure are in many
cases strikingly different.
One possible explanation for the differences in the
models of the MLSBK antibiotics bound to the ribo-
somes of the two species Hma and Dra is that Hma,
like most archaebacteria, has a G at position 2058, but
Dra, like most eubacteria, has an A at that position.
In eubacteria, A2058G mutations confer resistance to
MLSBK antibiotics, and as expected, Hma ribosomes
are resistant to them (Sanz et al., 1993). Indeed, a crys-
talline complex of erythromycin bound to the Dra large
subunit has been obtained using a drug concentration
of 0.1 mM (Schlu¨nzen et al., 2001), whereas erythromy-
cin does not bind to crystals of Hma large subunits
even at a concentration of 3 mM (J.L. Hansen, P.B.M.,
and T.A.S., unpublished data).
In order to determine whether or not the A/G differ-
ence at position 2058 accounts for the structural differ-
ences reported, we have determined the structures of
several MLSBK antibiotic complexes with Hma large
subunits containing mutations that should affect their
sensitivity to these drugs. Mutant ribosomes were ob-
tained from several different strains of Hma carrying
rRNA operons in which the 23S rRNA gene of rrnA
cistron is mutated from G to A at position 2058 and
from a strain in which the gene for L22 has the three
amino acid deletion that in E. coli reduces sensitivity to
macrolides without reducing their affinity for the ribo-
some. The erythromycin affinity of Hma large subunits
containing the G2058A mutation is about 104 times
higher than that of wild-type, and using this mutated
Hma large ribosomal subunit, its crystal structure with
erythromycin bound has been obtained. We have also
determined the structures of this mutated large ribo-
somal subunit bound to telithromycin, azithromycin,
clindamycin, quinupristin, and virginiamycin M and S
together, which are streptogramins of the A and B
types, respectively.
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258Table 1. Crystallographic Statistics
Data Collection
Crystal Antibiotic Res (Å)a I/σb Rmergec Completed Redd λe
50% G2099A Erythromycin 50.0–2.65 (2.74–2.65) 24.4 (1.9) 7.0 (71) 99.2 (94.0) 6.3 1.10
33% G2099A Telithromycin 50.0–2.60 (2.69–2.60) 22.5 (1.8) 7.8 (80) 99.0 (91.9) 6.5 1.10
100% G2099A Azithromycin 50.0–2.40 (2.49–2.40) 22.6 (1.8) 6.2 (71) 95.7 (72.1) 4.8 1.10
33% G2099A Virginiamycin M + S 50.0–2.85 (2.95–2.85) 15.5 (2.2) 8.2 (59) 99.8 (99.9) 3.5 1.10
33% G2099A Clindamycin 50.0–3.00 (3.11–3.00) 11.2 (1.8) 10.8 (67) 98.2 (96.6) 4.1 1.10
100% G2099A Quinupristin 50.0–3.00 (3.11–3.00) 9.4 (1.9) 13.2 (62) 91.1 (92.6) 4.7 1.10
L22(3aa) — 50.0–2.90 (3.00–2.90) 10.4 (2.0) 9.1 (60) 97.2 (97.2) 3.0 1.08
Model Refinement
Crystal Antibiotic Res (Å)a I/σb Rcrystf Rfreeg Bondh Angh Bi
50% G2099A Erythromycin 30.0–2.65 (2.74–2.65) (1.9) 17.7 21.4 0.005 1.0 75
33% G2099A Telithromycin 30.0–2.60 (2.69–2.60) (1.8) 18.2 21.9 0.005 1.0 65
100% G2099A Azithromycin 30.0–2.40 (2.49–2.40) (1.8) 19.0 22.9 0.005 1.0 37
33% G2099A Virginiamycin M+S 30.0–2.80 (2.90–2.80) (1.7) 17.4 22.1 0.005 1.0 35, 42
33% G2099A Clindamycin 30.0–3.00 (3.11–3.00) (1.8) 17.0 22.8 0.005 1.0 57
100% G2099A Quinupristin 30.0–2.90 (3.00–2.90) (1.1) 17.0 22.3 0.005 1.0 55
L22(3aa) — 30.0–2.80 (2.90–2.80) (1.4) 18.5 24.3 0.006 1.1
a Resolution range for X-ray diffraction data followed in parenthesis by resolution range of high-resolution bin.
b I/σ, intensity/error.
c Rmerge = {ShklSi|Ii(hkl) − ì(hkl)|}/{ShklSi[Ii(hkl)]}, where ì(hkl) is the average intensity of reflection (hkl), and Ii(hkl) is the ith observation.
d Complete, completeness of data; Red, redundancy of data.
e Wavelength of X-rays in Å.
f Rcryst = {Shkl|Fc(hkl) − Fo(hkl)|}/{Shkl[Fo(hkl)]}, for data used in refinement, where Fc(hkl) is the calculated model-based amplitude for reflection
hkl and Fo is the measured amplitude.
g Calculated the same as Rcryst for a test reflection set which was excluded from all refinement.
h Bond and Ang, RMS deviations from standard bond lengths in Å, and bond angles in degrees.
i B factor in Å2 refined for all bound antibiotics while setting their occupancy to one.Even though the G2058A mutation greatly increases 1
(the affinity of Hma ribosomes for macrolides, the loca-
tion and conformation of the macrolide rings bound to (
sthese ribosomes are only slightly different from those
bound to wild-type large subunits from the same organ- t
Gism (Hansen et al., 2002a) and thus still differ markedly
from those reported for macrolide complexes with the t
pDra subunit (Berisio et al., 2003; Schlu¨nzen et al., 2001).
Thus, the differences in the models reported for macro- a
olide antibiotics bound to Hma and Dra cannot be attrib-
uted to the sequence difference at position 2058. w
wThe conformation of L22 containing the deletion that
causes resistance differs from its conformation in wild- f
2type large ribosomal subunits. The loop of L22 bends
away from the tunnel wall, widening the gap between m
aL22 and L4, but no structural change is observed in the
region where erythromycin binds. These observations p
brationalize the chemical protection data reported earlier
for such mutants in E. coli (Gregory and Dahlberg, t
s1999) but provide only hints as to why these ribosomes
are less sensitive to inhibition by erythromycin. (Unless c
ootherwise stated, in the text that follows, nucleotide or
protein residue numbering will refer to Hma, not E. coli, t
wbut the equivalent number in E. coli will be given in pa-
rentheses.) m
TResults
L
TThe Preparation of Large Ribosomal Subunit
Crystals Containing G2099A 23S rRNA u
cUsing a modified version of a gene replacement system
developed for Halobacterium halobium (Krebs et al., s993) and sequence information about H. marismortui
Hma) posted on the web by the DasSarma group
[http://zdna2.umbi.umd.edu], Hma contigs version 2),
trains of Hma were produced that contain either mu-
ated 23S rRNA genes or a mutated L22 gene (D.T.,
.B., P.B.M., and T.A.S., unpublished data). In many of
hese experiments, G2099A large subunits were pre-
ared from a strain containing two native rRNA operons
nd a single mutant rRNA operon, and hence the ratio
f large subunits containing the G2099A mutation to
ild-type large subunits was w1:2. A few experiments
ere done using large ribosomal subunits prepared
rom strains in which the ratio of mutant to wild-type
3S rRNA cistrons was either w1:1, or only a single,
utated 23S rRNA cistron was present. Southern blots
nd DNA sequencing of polymerase chain reaction
roducts confirmed the presence of the expected num-
er of rRNA operons in each strain and the identities of
he bases at position 2099. RNA sequencing demon-
trated that A2099 and G2099 containing 23S rRNA
istrons are produced in strains containing both kinds
f genes. The large ribosomal subunits obtained from
hese strains crystallize under the same conditions as
ild-type Hma large ribosomal subunits to produce iso-
orphous crystals (Ban et al., 2000).
he Structure of Erythromycin Bound to G2099A
arge Ribosomal Subunits from Hma
he highest resolution structure of a G2099A large sub-
nit with erythromycin bound was obtained from a
rystal containing 50% mutant subunits that had been
oaked with 1 mM erythromycin (Table 1). An unbiased
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259(Fo (mutant + drug) − Fo (wild-type − drug)) difference
electron density map calculated at 2.75 Å resolution
using data from this crystal (Figure 1A) clearly showed
the conformation and orientation of the bound drug.
Erythromycin lies on the floor of nascent peptide tun-
nel with the edges of its two sugars pointing toward the
ribosomal A and P sites. The 2#OH of its desosamine
sugar forms a hydrogen bond with the N1 of A2099
(2058). The side of its lactone ring facing the lumen of
the tunnel is hydrophilic. It includes two axially orientedFigure 1. Electron Density Maps of MLSBK
Drugs Bound to G2099A Large Ribosomal
Subunits
(A)–(F) are unbiased difference electron den-
sity maps computed using (Fo(mutant +
drug) − Fo(wild-type − drug)) differences as
amplitudes and wild-type phases, which
show the position and conformation of: (A)
erythromycin at a resolution of 2.75 Å, (B) tel-
ithromycin at 2.75 Å, (C) azithromycin at
2.40 Å, (D) clindamycin at 3.00 Å, (E) quinu-
pristin at 3.00 Å, and (F) virginiamycin M and
S together at 2.85 Å. The reoriented base of
A2103 is included in (E) and (F). The contour
level of the electron density is 3.5 σ in (A),
(B), and (D), 4.5 σ in (C) and (E), and 6 σ in
(F). The resolutions of the erythromycin and
telithromycin difference maps shown were
determined by the resolution of the isomor-
phous native data set used, which was lower
than that of the drug/ribosome data sets ob-
tained (Table 1).
(G) Chemical structures of erythromycin, teli-
thromycin, azithromycin, clindamycin, virginia-
mycin S/quinupristin and virginiamycin M.hydroxyl and two axially oriented carbonyl oxygens. In
contrast, the face of the lactone ring that contacts the
tunnel wall is hydrophobic. It contains no hydrogen
bond donors or acceptors, but it does include three
methyl groups that insert into the hydrophobic pocket
formed by base of A2100 (A2059), the hydrophobic, C2
edge of A2099 (A2058), and the base and sugar of
G2646 (C2611) (Figure 2C). The snug fit of this face of
erythromycin with the tunnel wall would be altered both
sterically and chemically by addition of a hydrophilic
Cell
260Figure 2. Interactions of Macrolides with
G2099A Large Ribosomal Subunits
(A) A (Fo(mutant + drug) − Fo(wild-type −
drug)) difference map calculated using wild-
type phases shows positive 4 σ density
(black) for erythromycin and a negative 4 σ
peak (red) at N2 of G2099.
(B) No convincing difference density is ob-
served when erythromycin is soaked into
wild-type H. marismortui 50S crystal with
w3 mM concentration (left), but when it is
soaked into 50S crystals containing 33%
G2099A mutants, clear density is observed
when the drug concentration is 3 M (right).
(C) Erythromycin binds in the hydrophobic
pocket formed by residue A2100 (A2059),
A2099 (A2058), and G2646 (C2611), with its
desosamine oxygen hydrogen bonded to
A2099N1.
(D) Telithromycin binds in the hydrophobic
pocket formed by residue A2100, A2099, and
G2646 the way erythromycin does, with its
alkyl-aryl extension making an additional
stacking interaction with the base of C2644
(U2609) and a hydrogen bond to the 2#OH of
C2644 (U2609) .
(E) The lactone rings of erythromycin and
telithromycin bound to Hma ribosomes are
perfectly superimposable.
(F) Comparison of azithromycin bound to
G2099 (blue) and G2099A (yellow) ribo-
somes. The N2 of a G was modeled onto res-
idue A2099. The two structures compared
were aligned by least squares superimposi-
tion of ribosomal RNA phosphorus atoms.group to this part of the tunnel wall, e.g., the N2 of a G a
rat position 2099 (2058).
The presence of the G2099A subunits in these crys- d
otals is clearly evident in difference electron density
maps. Figure 2A shows the relevant portion of an unbi- F
fased difference electron density map calculated using
(Fo(mutant + drug) − Fo (wild-type − drug)) amplitudes S
fand wild-type, apo phases. The mutant crystals used
contained w33% G2099A large subunits and were t
whighly isomorphous to the wild-type crystals to which
they are compared. In addition to positive electron den-
tsity for erythromycin, this map includes a negative 4 σ
peak at the position occupied by the N2 of G2099 in s
sthe wild-type large subunit (Figure 2A), proving that the
nucleotide at position 2099 is an A in the mutant large s
tsubunits.
A lower-bound estimate of the change in the binding T
daffinity of the Hma large ribosomal subunit for erythro-
mycin afforded by the G2099A mutation was obtained o
aby a crystallographic titration. Erythromycin was soaked
into crystals containing 33% G2099A subunits at con- T
scentrations of 30 M, 3 M, 1 M, and 0.3 M. DifferenceFourier maps were computed between the observedmplitude data obtained from crystals containing eryth-
omycin at each of these concentrations and native
ata sets. To determine the concentration at which the
ccupancy of the drug began to diminish, difference
ourier maps were also calculated between data sets
rom crystals containing different drug concentrations.
ince crystals used in this titration experiment were all
rom the same batch of subunits, it was not necessary
o establish the exact fraction of mutant subunits; it
as the same in all crystals.
While the difference map between crystals of wild-
ype subunit soaked in 3 mM erythromycin and native
howed no convincing difference density, the corre-
ponding map using data from the 33% G2099A crystal
oaked in 3 M erythromycin showed full density for
he bound drug at a contour level of 3.5 σ (Figure 2B).
he same native data set was used for calculating both
ifference maps, and the cross-R factors between each
f the two data sets from the crystals soaked in drug
nd the same native data set are essentially identical.
hus, the contour levels of the two difference maps
hould correspond.
Analysis of data from the whole titration series re-
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261vealed that the erythromycin dissociation constant of
G2099A large subunits from Hma is at least 104 times
smaller than that of wild-type. Difference Fourier maps
computed between amplitudes obtained from crystals
soaked in 3 M and 30 M had no peaks, which means
that the occupancy of the erythromycin site is the same
in crystals soaked with the drug at those concentra-
tions. However, while the electron density for the drug
in difference maps calculated using (Fo(1 M erythro-
mycin complex) − Fo(native)) amplitudes was clear, the
contour level had to be lowered to 2.5 σ, and the differ-
ence map calculated between data obtained from crys-
tals soaked in 1 M erythromycin and those soaked in 3
M erythromycin showed negative density for the drug.
Thus, as the erythromycin concentration drops from 3
M to 1 M, its occupancy in these crystals drops ap-
preciably. The dissociation constant, however, could be
significantly below 1 M, since it is possible, indeed
likely, that at 1 M and below occupancy was limited
by diffusion. Since erythromycin binding to wild-type
Hma large ribosomal subunit is barely detectable at w3
mM but its binding to G2099A subunits can be de-
tected below 1 M, difference between the dissociation
constants of wild-type and G2099A mutant subunits is
at least 104.
The Structures of Other Antibiotics Bound
to the Mutated Large Subunit
Azithromycin
A structure of azithromycin, a 15-membered macrolide
derived from erythromycin, bound to 100% G2099A
Hma ribosomes at a resolution of 2.40 Å (Table 1)
showed that the two drugs bind to the ribosome in al-
most exactly the same way (compare Figure 1C with
Figure 1A; see also Figure S2 in the Supplemental Data
available with this article online).
Telithromycin
Telithromycin is a semisynthetic derivative of erythro-
mycin in which the cladinose sugar linked to C3 of the
lactone ring of erythromycin is replaced by a keto
group, the hydroxyl group at C6 is methylated, and the
C11/C12 position is extended by a carbamate N substi-
tuted with an alkyl chain that ends in two aromatic het-
erocycles. We have established the structure of telithro-
mycin bound to 33% G2099A crystals (Figure 1B) at a
resolution of 2.60 Å (Table 1). It binds to G2099A mutant
ribosomes in almost exactly the same way as erythro-
mycin. Its lactone ring and desosamine sugar superim-
pose on those of erythromycin almost perfectly (Figure
2E). The differences in ribosome interactions between
the two drugs reflect differences in their lactone ring
derivatization. Telithromycin’s alkyl-aryl C11/C12 sub-
stituent folds across the drug’s lactone ring so that its
pyridine group stacks on the base of C2644 (U2609)
(Figures 2D and S3).
Clindamycin
Clindamycin is a semisynthetic derivative of lincomycin
that is used for treatment of diseases caused by gram-
positive organisms. The structure of clindamycin bound
to G2099A large ribosomal subunits has been deter-
mined at a resolution of 3.00 Å (Table 1). The portion of
the unbiased ((Fo(mutant + drug) − Fo(wild-type - drug))
difference map that includes the drug is shown in Fig-
ure 1D.Clindamycin binds to the floor of the peptide tunnel
in an elongated conformation, with its long axis more
or less parallel to the axis of the exit tunnel. Its propyl
pyrrolidinyl group occupies the same cleft as the
O-methyl tyrosine residue of the A-site substrate CC-
puromycin (Hansen et al., 2002b), and the binding site
of its galactose group overlaps with the site occupied
by the desosamine sugar of macrolides. Clindamycin is
oriented and its binding stabilized by hydrogen bonds
with rRNA (Figure 3A). The 2OH of its galactose moiety
hydrogen bonds to the N1 of A2099, and 3OH forms
hydrogen bonds with the N6 of A2099 and the non-
bridging phosphate oxygen of G2540 (G2505). In addi-
tion, the 4OH of its galactose moiety hydrogen bonds
to the 2#OH of A2538 (A2503) and N6 of A2100 (A2059),
and the nitrogen atom of the peptide bond linking its
galactose moiety to its pyrrolidine group forms a hy-
drogen bond with the 2#OH of G2540 (G2505).
Virginiamycin M and S
Virginiamycin M and S (a.k.a. streptogramin A and B)
are chemically unrelated, macrocyclic lactone pepto-
lides that are produced simultaneously by Streptomy-
ces virginiae and synergistically inhibit the growth of
gram-positive bacteria (Cocito, 1979). We have solved
the structure of virginiamycin M and S bound to the
large subunit at a resolution 2.85 Å from a crystal con-
taining 33% G2099A mutant ribosomes that had been
soaked with a saturating concentration of a natural vir-
giniamycin mixture containing about 100 M of S and
600 M of M (Table 1). A portion of the unbiased
electron density map calculated at 2.85 Å resolution
using amplitudes ((Fo(mutant + drug) − Fo(wild-type −
drug)) show the drugs bind adjacent to each other with
the reoriented base of A2103 stacked between them
(Figure 1F).
In G2099A ribosomes, virginiamycin M binds at the
beginning of the peptide exit tunnel at a site that over-
laps those occupied by both A- and P-site substrates,
as it does in wild-type Hma large ribosomal subunits
(Hansen et al., 2003). Its largely hydrophobic macro-
cyclic lactone ring fits tightly over hydrophobic base
planes of A2486 (A2451) and G2102 (G2061). Its C2 iso-
propyl group is inserted underneath the base of U2620
(U2585), forming a favorable stacking interaction, and
its hydroxyl group at C13 forms a hydrogen bond with
the 3# oxygen of A2538 (A2503). The conjugated amide
group (C6/N7) of its lactone ring occupies the position
that A2103 (A2062) normally assumes, causing its base
to rotate away from the tunnel wall by about 90° into
the tunnel lumen. This enables the conjugated amide
group of the M component to stack on base of A2103,
and its carbonyl oxygen to form a hydrogen bond with
2#OH of A2103 (Figure 3B). The same movement of
A2103 was observed when virginiamycin M binds to the
wild-type large subunit (Hansen et al., 2003).
Virginiamycin S, which binds adjacent to virginia-
mycin M in a site that is further down the exit tunnel
and is partially supported by its interactions with the M
component, occupies space in the lumen of the tunnel.
In its overall conformation, virginiamycin S looks like a
cup, with its phenyl and pyrrolidine rings stacked on
each other to form the bottom of the cup. The hy-
drophobic edges of those rings stack on the base of
U2645 (C2610).The repositioning of the base of A2103 appears to be
Cell
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fycin M on virginiamycin S binding, a saturating con-
igure 3. Interactions of Other MLSBK Drugs with G2099A Large
ibosomal Subunits
A) Clindamycin interacts with rRNA through an extensive hydrogen
ond network. N6 of A2099 acts as an obligatory hydrogen bond
onor to 3OH of the galactose moiety of clindamycin.
B) Binding of virginiamycin M (VM) to the large subunit causes the
ase of A2103 to reorient so it can stack on the C18 pyridinyl group
f virginiamycin S (VS), thus forming a binding pocket for VS.
C) Comparison of quinupristin bound to G2099A ribosomes and
irginiamycin S bound to G2099 ribosomes as part of virginiamycin
+ S pair. N2 of a G was modeled onto residue A2099 and is 2.3 Å
rom the nearest atom in quinupristin.prerequisite for high affinity binding of virginiamycin
to the ribosome. The repositioned base not only
erves as a platform on which the conjugated [(3-
ydroxy-2-pyridinyl)carbonyl] amino group from C18 of
irginiamycin S can stack, it also brings the N6 and N1
f A2103 close enough to the C14 carbonyl oxygen and
he N16 amide nitrogen to enable two hydrogen bonds,
espectively (Figure 3B). It is presumably the stacking
f this reorientated A on virginiamycin S that results in
he cooperative binding observed between these two
omponents.
The S component also makes some hydrophobic
ontacts with the ribosome. The phenyl residue in C3 of
he virginiamycin S lactone ring stacks onto the ribose
oiety of C2644 (U2609) and thereby displaces its base
y about 45° compared to the native structure of the
arge subunit. An additional stacking interaction is ob-
erved between the aliphatic stretch of C17 to C19 onto
he base of pseudouridine 2621 (U2586).
Binding of virginiamycin S to the large subunit is also
tabilized by metal ion interactions. A magnesium ion
oordinates the hydroxyl and carbonyl oxygens of the
onjugated [(3-hydroxy-2-pyridinyl)carbonyl] amino group
rom C18 of the drug. The octahedral coordination of
his magnesium ion is completed by four additional
ater molecules of which one is in hydrogen bond dis-
ance to a nonbridging phosphate oxygen of C2476.
he Effect of G2099A Mutations
n Virginiamycin S Binding
he occupancies of the virginiamycin M and S sites in
hese mixed mutant and wild-type crystals are about
he same, which implies that under these conditions, it
akes no difference whether large subunits have an A
r a G at position 2099. This was not entirely unex-
ected because in E. coli, A2058U mutants do not bind
irginiamycin S, but in the presence of virginiamycin M,
igh-affinity binding of virginiamycin S occurs (Vannuf-
el et al., 1992). Knowing virginiamycin S binds to both
he G2099 or A2099 50S subunit in the presence of vir-
iniamycin M, residue 2099 was modeled as a G during
efinement. The N2 of G2099 in the refined structure is
.0 Å from the closest atom in the C9 benzyl group of
irginiamycin S. This juxtaposition should destabilize
he binding of virginiamycin S and may explain why
2058G (E. coli ) mutation confers streptogramin B re-
istance.
inding of Virginiamycin S Alone
o gain further insights into the influence of virginia-
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263centration (w300 M) of the virginiamycin S derivative
quinupristin was soaked into crystals of 100% G2099A
large ribosomal subunits. An unbiased ((Fo (mutant +
drug) − Fo (wild-type − drug)) difference map at 3.00 Å
resolution shows that quinupristin binds at about the
same position as that of virginiamycin S in the structure
of the complex containing both virginiamycin compo-
nents (Figure 1E). The base of A2103 adopts the same
position that it does when both virginiamycin M and S
bind (Figure 1E). This suggests that the reorientation
of A2103 caused by the M component completes the
binding pocket for the S component, thereby reducing
the energy cost of binding of the S component.
The position occupied by quinupristin in these com-
plexes is almost identical to that occupied by virginia-
mycin S when both virginiamycin components are
present (Figure 3C). In addition to slight differences in
ring atom positions that are probably not significant ex-
perimentally, the C9 dimenthyl amino benzyl group of
quinupristin is somewhat closer to residue 2099 than
the corresponding group of virginiamycin S, a finding
which supports the hypothesis that the benzyl group at
C9 of streptogramin B-type drugs clash sterically with
the N2 of Gs in position 2099. Resistance to strepto-
gramin B caused by the methylation of the N6 of A2099
(2058) could result from a rotation of the modified base
toward the position of the C9 benzyl group caused by
a need to increase the contribution of the methylated
amine in stacking.
The Structure of the Large Subunit
Containing an L22 Mutant
The three amino acid deletion (122–124) in L22 of Hma
is equivalent to the deletion mutation in E. coli that re-
moves Met82, Lys83, and Arg84 from the conserved
C-terminal β hairpin of L22 from E. coli and confers
erythromycin resistance to E. coli ribosomes without re-
ducing their affinity for the drug (Chittum and Champ-
ney, 1994; Wittmann et al., 1973). The structure of large
subunits containing this mutation was solved at a reso-
lution of 2.90 Å (Table 1).
The three residue deletion from Hma L22 causes its
entire C-terminal β hairpin to move away from its nor-
mal interaction with the RNA of the tunnel wall, near
the erythromycin site, and lodge in the lumen of the
peptide exit tunnel closer to its exit (Figure 4C). A dif-
ference Fourier map calculated using (Fo(L223aa) −
Fo(native)) as coefficients and contoured at +2.5 σ
showed the new position of the L22 loop, which is now
bent away from its former orientation by approximately
90° (Figure 4B). Trace density was seen nearby, which
suggests that another conformation of the loop is pos-
sible in this region, but it was not well enough con-
nected to be modeled.
The same difference Fourier map contoured at −6 σ
indicated not only that the 19 residue β hairpin of L22
is not in its normal position but also that three nearby
rRNA residues change location (Figure 4A): A1689
(A1614), A841(G748), and U840(U747). Residue U840
moves the furthest and in the mutant fills a location that
is normally occupied by the tip of L22 β hairpin. How-
ever, the difference electron density also indicated the
existence of another conformation for U840, implying
this residue is mobile in the absence of the L22 hairpin.A structure of a tylosin complex with these L22 mutant
ribosomes shows tylosin binds as previously observed
for wild-type ribosomes; however, its mycinose sugar
stabilizes U840 in its wild-type position (data not
shown).
Discussion
Mutation of G2099A and Its Implication
on the Binding of Macrolides
The effect of G2099A mutations on the affinity of H. mar-
ismortui (Hma) large subunits for erythromycin is of the
same order of magnitude, 104, as that anticipated on
the basis of studies of E. coli ribosomes carrying an A
to G mutation at that same position (Vester and Douth-
waite, 2001). Chemical modification data obtained with
E. coli indicate that the concentration of erythromycin
necessary to protect residues 2058 and 2059 in ribo-
somes from strains that have a G at position 2058 is
also about 104 times higher than the concentration re-
quired to obtain the same effect in ribosomes from
strains that have an A at that position (Douthwaite and
Aagaard, 1993).
The reason soak-in experiments done at ligand con-
centrations below 1 M provide only upper bound lim-
its for dissociation constants is that the rate at which
ligands diffuse into crystals becomes rate limiting at
those concentrations and because the total number of
ligand molecules in the solutions in which crystals are
soaked becomes comparable to the number of drug
binding sites in the crystals. Therefore, it is probable
that the erythromycin dissociation constant of G2099A
large ribosomal subunits from Hma is substantially less
than the data presented here appear to document, i.e.,
<1 M. Thus, even though we cannot exclude the pos-
sibility that the erythromycin dissociation constant of
G2099A Hma large subunits might still be 100-fold
greater than that reported for E. coli ribosomes, w0.01
M (Pestka, 1974), the large size of the decrease in
dissociation constant the data support gives us confi-
dence that the MLSK antibiotic/Hma large subunit struc-
tures reported here are pharmacologically relevant.
Macrolides bind to Hma large ribosomal subunits
containing the G2099A mutation almost exactly the
same way that they bind to wild-type Hma large sub-
units. Comparison of the structure of azithromycin
bound to wild-type large subunits (Hansen et al., 2002a)
with that of the same drug bound to G2099A large sub-
units (Figure 2F) shows no change in drug orientation
or conformation, but only a small −1 Å shift in position.
This shift undoubtedly reflects the steric clash that the
hydrophilic N2 of G at 2099 in the wild-type particle
would have with the drug’s C4 methyl group and the
middle of its lactone ring if positioned as in the G2099A
mutant. If the residue at position 2099 in the erythromy-
cin complex reported here were a G instead of an A,
the N2 of G2099 would be only 2.7 Å from C4 methyl of
the drug’s lactone ring.
While it might seem surprising that the large increase
in erythromycin affinity that accompanies the G2099A
mutation of Hma large subunit is not accompanied by
significant changes in the ways macrolides bind, a sim-
ilar phenomena has already been observed in HIV re-
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264Figure 4. Structure of the Large Subunit Containing the 3aa L22 Mutant
(A) A (Fo(L223aa) − Fo(native)) difference electron density map calculated to a resolution of 2.9 Å and contoured at −6 σ shows that L22’s
entire C terminus β hairpin has moved away from its native position and several nearby rRNA residues have changed location.
(B) Superposition of a 2.9 Å resolution (Fo(L223aa) − Fo(native)) difference map (in green) and a (2Fo(L223aa) − Fo(native)) difference electron
density map (in blue) that were contoured at +2.5 σ and +1 σ, respectively, that shows the fading of the 2Fo − Fo density where the loop starts
to bend and one of the new loop positions evident in Fo − Fo density.
(C) Schematic showing the relative positions of the L4/L22 gate, the erythromycin binding site, and the movement of L22 β hairpin caused by
the 3aa mutation.verse transcriptase (RT) where nonnucleoside inhibitors (
ebind almost identically to resistant mutants of RT and
to wild-type RT (Das et al., 1996). In fact, most of the s
tpotential for stabilizing interactions between drugs and
wild-type targets is preserved in resistance mutants, a
sand binding is often only slightly perturbed.
l
tTelithromycin Binds Tighter Than Erythromycin
Because It Makes Additional Interactions 1
pwith the Ribosome
Telithromycin binds to the ribosome with its lactone t
(ring oriented almost the same as the lactone ring of
erythromycin but with its added alkyl-aryl side chain U
extended above its lactone ring so that it stacks on
C2644 (U2609). This additional stacking interaction is V
Wconsistent with biochemical data obtained in E. coli
showing that telithromycin binding protects U2609 pE. coli ) from chemical attack more effectively than
rythromycin (Garza-Ramos et al., 2001). This “extra”
tacking interaction and the hydrogen bond formed be-
ween the nitrogen of pyridine group in telithromycin’s
klyl-aryl side chain and the 2#OH of C2644 ribose
ugar may also explain why the binding affinity of te-
ithromycin for wild-type bacteria ribosomes is w10
imes higher than that of erythromycin (Hansen et al.,
999). In contrast, this structure does not support the
roposal that the enhanced affinity of telithromycin for
he ribosome might result from interactions with U845
A752) (Hansen et al., 1999; Xiong et al., 1999); residue
845 is 6.5 Å from the closest atom of telithromycin.
irginiamycin: A2103 May Be Critical for Synergy
e have observed a conformational effect that may ex-
lain the binding cooperativity of virginiamycin M and
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265Figure 5. A Model of the Eight N-Terminal Amino Acids of the ermC Operon Leader Peptide Bound at the PTC End of the Peptide Exit Tunnel
The molecular surface of the interior of the nascent peptide exit tunnel is shown for the wild-type large ribosomal subunit (A and B) and the
L22 deletion mutant ribosome (C). In all three views, it is cut in half along its length to show diameter of the tunnel. In its lower part, polyalanine
in α-helical conformation (red) is modeled to mark the general trajectory of the tunnel. Wild-type L22 (white) and L4 (magenta) are shown as
ribbons. In (A), the erm peptide (with a sequence of Met-Gly-Ile-Phe-Ser-Ile-Phe-Val) is depicted in a position that would enable it to pass
over bound erythromycin (purple) without interfering sterically with either the drug or the surrounding ribosome.
(B) The model in (A) is rotated by 90° to show that by the eighth residue, the peptide has essentially cleared the drug and its N-terminal
residue is close to the β hairpin of L22.
(C) In the L22 mutant ribosome, the L4/L22 gate becomes almost twice as wide as it is in the wild-type ribosome as a result of the movement
of the β loop of L22. This gives the elongating peptide more room to get past this part of the tunnel, although the wild-type L4/L22 gate does
not seem so constricted as to prevent peptide passage even when erythromycin is bound.S in crystals and their pharmacological synergism. The
dissociation constant of vernamycin A (=virginiamycin
M) bound to E. coli ribosomes is about 1.8 × 10−8 M
(Ennis, 1971), and that of virginiamycin S is about 4.0 ×
10−7 M (Parfait et al., 1978). However, prior binding of
the M component increases the affinity for the S com-
ponent by about 6-fold (Parfait et al., 1978), but the S
compound has no impact on the affinity of the M com-
pound (Cocito and Di Giambattista, 1978). The observa-
tion that the M component binds to the wall of peptide
tunnel, but the S component binds more in the lumen
of the tunnel probably explains why the affinity of vir-
giniamycin M is higher than that of virginiamycin S. The
repositioning of A2103 (A2062) that follows the binding
of virginiamycin M may well explain their synergy, as
suggested previously by Hansen et al. (2003), and more
recently by Harms et al. (2004).
The Three Amino Acid Deletion in L22
and Macrolide Resistance
The three amino acid deletion mutation in L22 exam-
ined here was originally discovered in E. coli strains
that are resistant to erythromycin even though their ri-
bosomes still bind erythromycin (Chittum and Champ-ney, 1994; Wittmann et al., 1973). Later, the same dele-
tion mutation was found in Haemophilus influenzae
strains selected for clarithromycin resistance in vitro
(Clark et al., 2002). When the corresponding deletion is
made in Hma L22, the entire β hairpin moves away from
the tunnel wall and repositions itself further down the
tunnel. The electron density for the loop in the mutant
suggests that it binds loosely there in several different
ways; the refined B factors for this part of L22 are
120 Å2. It seems unlikely that a hairpin so flexibly posi-
tioned in the lumen of the peptide exit tunnel would
pose a barrier to the passage of nascent peptides
through the tunnel.
The relocation of L22 observed in our mutant struc-
ture explains almost all of the chemical protection data
available which comes from E. coli, the organism in
which mutations of this type were first isolated. Four of
the five residues that have increased chemical reactivi-
ties in E. coli strains carrying the corresponding L22
mutant (Gregory and Dahlberg, 1999) are located in the
immediate vicinity of the region vacated by the β hairpin
of L22 in the mutant, and their exposure to solvent is
greatly increased. The only residue reported to have an
increased chemical reactivity in L22 mutants that is not
Cell
266Figure 6. Differences between Models of MLSBK Antibiotics Bound to the H. marismortui (Hma) and D. radiodurans (Dra) Ribosomes
(A–H) Hma or Dra models of erythromycin, telithromycin, clindamycin, and virginiamycin S are compared to their small molecule crystal
structures by least squares alignment of their lactone ring or galactose ring atoms. The conformation of antibiotics bound to Hma ribosomes
are all very close to the corresponding small molecule conformations, as can be seen for (A) erythromycin, (B) telithromycin, (C) clindamycin,
and (D) virginiamycin S. However, the models for these compounds bound to the Dra large subunit are very different, with erythromycin
having its cladinose sugar sticking perpendicular to its lactone ring (E), telithromycin having a highly squashed lactone ring with many atoms
unacceptably close together (F), clindamycin’s pyrrolidinyl group pointing into a different direction by a peptide bond flip (G), and quinupristin
having its conjugated C18 group twisted (H). Aligned by least squares superimposition of rRNA phosphorus atoms, neither the Dra model of
erythromycin (I) nor the Dra model of telithromycin (J) fit the corresponding Hma models. In both, the lactone ring of the Dra model tilts away
from the hydrophobic binding pocket, and the alkyl-aryl extension of telithromycin goes in a completely different direction.
(K) In the models proposed for erythromycin and telithromycin bound to the Dra ribosome, the lactone rings of the two compounds are tilted
relative to each other by about 50°.close to the β hairpin of L22 is G2385 (G2351), and it is t
tso far away (w90 Å) we are not sure what that observa-
tion means. Thus, these correlations give us confidence d
Ithat the effect of those L22 deletions is the same in
Hma as it is in E. coli. s
hThe structure of the macrolide binding site in Hma
subunits containing the L22 deletion mutation is unal- rered, which explains why these mutations do not alter
he affinity of the ribosome for macrolides. However, it
oes not explain why they confer macrolide resistance.
n the presence of macrolides, ribosomes synthesize
hort peptides rather than full-length proteins, and it
as long been believed that this results because mac-
olides prevent the passage of nascent peptides down
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267the exit tunnel of the large ribosomal subunit. In gene-
ral, the published structures of complexes between
macrolides and the large subunit support this hypothe-
sis. We and others have suggested that the physiologi-
cal effect of macrolides results from their sterically
blocking the lumen of the tunnel (Hansen et al., 2002a),
and this may be true for some of them, particularly the
larger ones. However, if this were the only mechanism
of the macrolide inhibition, then the alteration in the
conformation of L22 we observed should have no effect
on macrolide phenotype since erythromycin still binds.
Recent biochemical data suggest that the steric
block model is incomplete for some macrolides, like
erythromycin. Recent data show that erythromycin in-
duces dissociation of peptidyl-tRNAs from the ribo-
some that carry peptides six, seven, or eight amino
acids long, with seven being the dominant length (Ten-
son et al., 2003). Using the structure of an Hma large
ribosomal subunit complex with a P-site substrate
(Hansen et al., 2002b) to place the C-terminal residue
of peptidyl-tRNAs, we have modeled these peptides
into the tunnel of a large subunit of H. marismortui with
erythromycin bound. The lumen of the tunnel is not so
occluded by erythromycin that a peptide cannot get
past it (Figures 5A and 5B). Furthermore, the N-terminal
residue of an eight residue long peptide would reach a
point in the tunnel that is essentially past the drug. It is
hard to see why a nascent peptide that has gotten this
far down the tunnel should not successfully pass
through its entire length. However, we note that just as
nascent peptides pass the bound macrolide site, they
must negotiate the constriction in the exit tunnel
formed by the conjunction of loops of L22 and L4 (Fig-
ure 5B), the part of the tunnel altered by the L22 muta-
tions that affect macrolide resistance (Figure 5C). Per-
haps, in the presence of erythromycin, it is difficult for
nascent peptides to get through this passage.
The structural consequences of this L22 deletion
have also been studied by cyroelectron microscopy.
Gabashvili and coworkers report that in E. coli 70S ribo-
somes containing the same L22 mutation (Gabashvili et
al., 2001), the diameter of the entire upper end of the
tunnel increases from w20 Å to w26 Å, and they sug-
gest that L22 mutants are resistant to macrolides be-
cause the lumen of the tunnel has become so large that
it can no longer be obstructed effectively by macro-
lides. The changes we see are smaller and less exten-
sive. The diameter of the tunnel expands from w10 Å
to w19 Å but only in the region where L4 and L22 come
together in the tunnel. Furthermore, as discussed
above, the mechanism of L22 resistance is likely to be
more complex, since macrolides bind to the tunnel en-
tirely above the region affected by L22 mutations. Ga-
bashvili et al. also suggested that the rRNA walls of the
tunnel become expanded when L22 is mutated this way
and speculated that RNA structural changes of this
type could conceivably enable the tunnel to function as
a peristaltic pump, facilitating the movement of peptide
down the tunnel. We see no changes in the backbone
positions of the RNA in the mutant and indeed deem
changes in the tunnel large enough to propel nascent
proteins down it unlikely.Differences between the Models of MLSBK
Antibiotics Bound to the H. marismortui
and D. radiodurans Ribosomes
The models for MLSBK antibiotics bound to ribosome
that we have presented here and previously (Hansen et
al., 2002a) are significantly different from those models
provided by the Yonath group (Berisio et al., 2003;
Harms et al., 2004; Schlu¨nzen et al., 2001) even though
Hma and Dra large subunits have drug binding sites
whose sequences are highly conserved. The structural
differences between the models fall into three cate-
gories: drug conformation, variation in the positions
adopted by drugs of the same class when bound to the
ribosome, and differences in proposed drug-ribosome
interactions. The observations described above indi-
cate that the differences between the models derived
for MLSBK antibiotics bound Hma and Dra large sub-
unit may not necessarily arise from sequence differ-
ences between the eubacterial and archaebacterial ri-
bosomes. The G2099A (2058) mutation in the Hma
subunit increases its affinity for erythromycin by the
same amount (at least 104) as the A2058G mutation in
the E. coli subunit decreases it. Further, the interactions
made by erythromycin in the G2099A mutant Hma ribo-
some should be nearly identical to those it makes in a
eubacterial ribosome since the only other base differ-
ence in the binding site between the two species af-
fects only a nonsequence-specific stacking interaction.
Crystal structures for most of the antibiotics de-
scribed here have been previously determined using
the pure compound. The conformations of all these an-
tibiotics when bound to the Hma large subunit are al-
most identical to the conformations they display as
isolated compounds. However, the conformations as-
cribed to these same molecules in their complexes with
the Dra large subunit are in many cases very different
(Table 2). For example, in both its small molecule crystal
structure and in our complex, the cladinose sugar of
erythromycin is in its low-energy chair conformation
(Stephenson et al., 1997), but in the erythromycin com-
plex with large subunit provided by Schlu¨nzen et al.
(2001) it is in the boat conformation. In addition, in the
Schlu¨nzen et al. structure, the cladinose sugar is axial
relative to the 14-membered lactone ring rather than
being equatorial to it, as it is in both our structure and
the small molecule crystal structure (Figures 6A and 6E).
In the case of clindamycin, the correspondence be-
tween the small molecule crystal structure and the
structure of the dug bound to the Hma large subunit is
again very close (Figure 6C). Clindamycin consists of a
pyrrolidinyl group linked to a galactose sugar by a pep-
tide bond (Figure 1G). In the structure reported by
Schlu¨nzen et al. (2001), the relationship between the
two rings differs by 180° (cis rather than trans) from that
seen in the small molecule structure (Figure 6G).
There is no small molecule structure for telithro-
mycin, but the structure of its close cousin HMR3004
(Agouridas et al., 1998), which differs only in the nature
of the alkyl-aryl group attached to C11/C12 carbamate,
reveals that the conformations of the aglycone back-
bone of 14-membered ketolides and 14-membered
macrolides are the same. However, in the telithromycin
complex with the large subunit structure of Berisio et
al. (2003), the aglycone backbone of the ketolide ring is
Cell
268Table 2. Comparison of Structures Reported for Antibiotics Bound to Large Ribosomal Subunits with the Structures Available in the
Cambridge Structural Database
Antibiotic (CSDa number) H. marismortui D. radiodurans (PDB number)
Erythromycin (NAVTAF) 0.745b 2.307 (1JZY)
Clindamycin 1c (SUPBIO) 0.312 2.100 (1JZX)
Clindamycin 2 1.017 1.868
Clindamycin 3 0.574 2.387
Telithromycin (GOPGAT) 0.260 1.799 (1P9X)
Virginiamycin S (KEFWUN) 0.779 1.733(1SM1)
a Cambridge Structural Database.
b Root mean square deviations are reported (in Å) for the optimal superposition of the structures being compared. Only atoms common to
both the small molecule structures and the antibiotic complex structures reported are aligned and compared.
c The different conformations observed for clindamycin 2-phosphate are indicated with numbers.squashed into a highly elongated form that is very dif- o
dferent from the rounded shape it assumes in crystals
of pure HMR3004, pure erythromycin, or in any of the 5
structures of the complexes between macrolides and
the large subunit that we have obtained (Figures 6B i
eand 6F).
Streptogramin B group compounds are cyclic hexa- r
ddepsipeptides that contain multiple peptide groups
which should be planar due to the partial double bond l
tcharacter of the peptide bond, consistent with the
small molecule structure that has been obtained for
tvernamycin Bα, another streptogramin B (Karle and
Flippen-Anderson, 1990). This structure shows that the s
gentire [(3-hydroxy-2-pyridinyl)carbonyl] amino group at-
tached to C18 is planar, consistent with its conjugated 2
istructure. Nevertheless, in the model proposed by
Harms and coworkers for the streptogramin B quinu- m
rpristin bound to the large subunit (Harms et al., 2004),
neither the peptide group nor the 3-hydroxyl of pyridine t
dand the nearby carbonyl group are planar. In addition,
the 3-hydroxyl pyridine group turns away from the loca- e
ation it assumes in small molecule structures, and the
backbone ring atoms fold together so that the drug no H
4longer looks like a cup (Declercq et al., 1978; Karle and
Flippen-Anderson, 1990; Figures 6D and 6H). t
sWhile it is certainly possible that the binding of the
MLSBK antibiotics to the Dra ribosome could result in n
bconformational alterations, such distortions would cost
free energy, which would decrease their affinities for the s
bribosome. Thus, the close similarities of the structures
of these antibiotics in isolation and bound to the Hma A
lribosome seem more plausible than the significant
changes in their structures reported for the Dra sub-
punit complexes.
The second area of difference between our results t
pand those of Yonath and coworkers is the way drugs of
the same chemical class interact with the ribosome. D
aFor example, in our models, all macrolides bind very
similarly, with the hydrophobic underside of their lac- t
[tone rings inserted into the hydrophobic cleft formed
by residues A2100 (A2059), A2099 (A2058), and G2646 u
t(C2611). In the case of macrolides with the same size
lactone rings such as erythromycin and telithromycin, c
alactone rings superimpose almost perfectly (Figure 2E).
This is not the case for the macrolide structures pre-
rsented by the Yonath group; the lactone rings of these
molecules are not modeled in the same location. For (
rexample, the orientation of the plane of the lactone ringf erythromycin in their erythromycin complex structure
iffers from that they observe for telithromycin by about
0° (Figure 6K).
The third area of difference is how the MLSBK drugs
nteract with their ribosome target. For example, mod-
ls of erythromycin or telithromycin bound to the large
ibosomal subunits of Dra and Hma posit dramatically
ifferent positions for the lactone rings of the macro-
ides and the alkyl-aryl C11/C12 substituent of the ke-
olides (Figures 6I and 6J).
Although there are substantial differences between
he ways erythromycin is reported to bind to large ribo-
omal subunits from the two species, the chemical and
enetic data in the literature (Vester and Douthwaite,
001) do not distinguish between them. For example,
n E. coli, A2059C (E. coli ) mutations are resistant to
acrolides. The authors of the Dra model for the eryth-
omycin complex suggest that a hydrogen bond be-
ween the N6 of their A2042 (A2059) and the 2#OH of
esosamine sugar explains this observation (Schlu¨nzen
t al., 2001). However, the distance between these two
toms is 5.3 Å in their deposited model, while in the
ma subunit complex, the corresponding distance is
.8 Å. Neither structure easily accounts for this resis-
ance mutation in question. On the other hand, the re-
istance of ribosomes to dimethylation of A2058 (E. coli
umbering) or its mutation to G can be rationalized by
oth structures, since both predict steric clashes that
hould destabilize macrolide binding. Furthermore,
oth the Dra and the Hma structures can explain why
2058C and A2058U mutations are resistant to macro-
ides.
It remains possible that there is a crystallographic ex-
lanation for at least some of the differences between
he Hma and Dra antibiotic models and the accuracy
roblems of the published Dra complexes (e.g., in the
ra sparsomycin complex there are no sparsomycin
toms closer than 3.9 Å to a ribosome atom, except
wo H-bond acceptors that are separated by 3.5 Å
Bashan et al., 2003]). However, since the Dra large sub-
nit models in the PDB lack protein side chains and
he observed structure factors for almost none of the
omplexes reported are available, an independent
nalysis of this possibility cannot be done.
In conclusion, the comparison of structures of large
ibosomal subunits with an A or G in position 2099
2058) complexed with MLSBK antibiotics enables us to
ationalize how A2058G (E. coli ) genotype is linked to
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269the MLSBK phenotype. In the case of macrolides, ke-
tolides, or streptogramin B class compounds, it is the
hydrophilic N2 of G intruding into the hydrophobic face
of either the macrolide lactone ring or the C9 benzyl
group of virginiamycin S that reduced drug binding. In
the case of lincosamides, the change of N6 to O6 upon
A to G mutation loosens the extensive hydrogen bond
network that clamps the galactose moiety of clinda-
mycin on to the rRNA. Yet another mechanism of resis-
tance is observed in the three amino acid deletion of
L22. This deletion in L22 dislodges its β hairpin at the
C terminus from its wild-type position into the lumen of
the tunnel, widening the gate formed between L4 and
L22. There are no changes in the rRNA backbone posi-
tion, which is consistent neither with an active role for
the rRNA in peptide elongation through the tunnel nor
with the notation of gross rRNA rearrangements caused
by drug-resistance mutations within this ribosomal
protein.
Experimental Procedures
The mutant strains of H. marismortui were constructed using pro-
tocols that are to be published (D.T., G.B., P.B.M., and T.A.S., un-
published data). The purification and crystallization of the large ri-
bosomal subunits from these mutant strains were performed as
described previously for the wild-type subunit (Ban et al., 2000).
Telithromycin was a generous gift from Aventis Pharma. Virginia-
mycin was acquired form Research Products International. All other
drugs and chemicals were purchased from Sigma. Antibiotics were
initially dissolved in dimethyl sulfoxide (DMSO) then added to the
standard subunit crystal stabilization buffer (Ban et al., 2000) to
yield a final drug concentration of 0.3 M to 1.0 mM and a DMSO
concentration of less than 4%. Crystals were incubated in these
stabilization solutions at 4°C for between 8 to 12 hr before being
flash-frozen in liquid propane. High-resolution data were collected
at beamlines 19ID at APS, 8.2.2. at ALS and ×25 at BNL. Data were
reduced using HKL2000 and scaled with SCALEPACK (Otwinowski
and Minor, 1997). Models for erythromycin, telithromycin, azithro-
mycin, clindamycin, virginiamycin, and quinupristin and their topol-
ogy and parameter files were constructed by connecting and/or
modifying, if necessary, the related small molecule structures
(Agouridas et al., 1998; Karle and Flippen-Anderson, 1990; Kosutic-
Hulita et al., 2001; Leban et al., 1994; Stephenson et al., 1997) using
standard stereochemical geometry and software, i.e., ChemDraw
3D in combination with XPLO2D (Kleywegt and Jones, 1998) and O
(Jones et al., 1991). The antibiotic models were initially fitted into
Fo − Fo difference electron density maps, using model phase from
the refined crystal structure of the large subunit at 2.4 Å resolution
(Klein et al., 2004). The structures of these complexes were refined
in an iterative process using CNS (Bru¨nger et al., 1998) for rigid
body refinement, energy minimization, and B factor refinement. In
all cases, partial occupancies of bound antibiotics were not
treated, i.e., they were all set to one. Instead, their refined B factors
if high reflect drugs binding only to a fraction of ribosomes in the
crystal. Coordinates are available at the Protein Data Bank with
accession numbers 1YHQ, 1YI2, 1YIJ, 1YIT, 1YJ9, 1YJN, and 1YJW.
Figures were made using ChemDraw, POVScript+ (Fenn et al.,
2003), and RIBBONS (Carson, 1997).
Supplemental Data
Supplemental Data include three figures and can be found with this
article online at http://www.cell.com/cgi/content/full/121/2/257/DC1/.
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